We extracted data from placebo-controlled randomized controlled trials, original articles, meta-analyses, and systematic reviews that reported cardiovascular, renal, and other positive outcomes of SGLT2 inhibitors in individuals with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.